Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03233802 · ClinicalTrials.gov registry record · NA

Individualized Assessment and Treatment for Alcoholism II

A NA study of Alcoholism, sponsored by UConn Health.

Completed
Registry status
NA
Development phase
173
Enrollment target
1
Study location

NCT03233802: Completed NA study of Alcoholism, sponsored by UConn Health.

NCT03233802 is a NA study of Alcoholism that has completed, run by UConn Health. The registered enrollment target is 173 participants, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03233802, a NA study of Alcoholism, has completed, sponsored by UConn Health.

COMPLETED
Registry status
NA
Development phase
173 participants
Enrollment target
1
Study location

Study Summary

The object of this study is to develop a treatment for alcohol use disorders that is more effective than current CB treatments. Through a 2009 R-21 pilot project the investigators developed a cognitive-behavioral (CB) treatment that employed cellphone-based experience sampling (ES) to collect detailed patient data, in near real-time, and that used those data to direct treatment for each patient based on his/her pattern of drinking and specific coping actions during high-risk situations. ES data included momentary assessments of situations, thoughts and feelings antecedent to drinking episodes, and the use of coping skills. That initial study of the Individualized Assessment and Treatment Program (IATP) showed promise. The present study is intended to extend the earlier findings, to compare IATP to a more active control treatment, and to evaluate long-term outcomes.

Primary Outcome

Proportion of days abstinent in the 90 days prior to each follow-up point

Conditions Studied

Interventions

  • BEHAVIORAL Individualized Assess & Treatment (IATP)
  • BEHAVIORAL Packaged Cognitive-Behavioral (PCBT)
  • BEHAVIORAL Case Management (CaseM)

Study Locations (1)

Connecticut

  • UConn Health - Farmington

Trial Details

FieldValue
Enrollment Target 173 participants
Start Date 2016-08-01
Est. Completion 2022-11-01
Phase NA
UConn Health

178 total trials

What the finished NCT03233802 record still lists

NCT03233802 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (53% lower).

The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 3 interventions - of which Individualized Assess & Treatment (IATP) is the first listed.

NCT03233802 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT03233802 about?

NCT03233802 is a clinical study titled "Individualized Assessment and Treatment for Alcoholism II". The object of this study is to develop a treatment for alcohol use disorders that is more effective than current CB treatments. Through a 2009 R-21 pilot project the investigators developed a cognitive-behavioral (CB) treatment that employed cellphone-based experience sampling (ES) to collect detail...

What is the current status of trial NCT03233802?

This trial is currently completed. It is a NA study. The enrollment target is 173 participants. The study started on 2016-08-01. Estimated completion is 2022-11-01.

What conditions does trial NCT03233802 study?

This clinical trial studies the following conditions: Alcoholism.

What interventions are being tested in trial NCT03233802?

The interventions under investigation include: Individualized Assess & Treatment (IATP) (BEHAVIORAL), Packaged Cognitive-Behavioral (PCBT) (BEHAVIORAL), Case Management (CaseM) (BEHAVIORAL).

Who is sponsoring clinical trial NCT03233802?

This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03233802 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcoholism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03233802's enrollment target sits among peer trials

173 22nd of 65 higher than 44 of 65 other Alcoholism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05568719 · 173 participants · Phase 3

    Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

  • NCT07070115 · 173 participants · NA

    Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

  • NCT07150832 · 173 participants · NA

    Efficacy of the I-CARE Digital Health Intervention

  • NCT01000259 · 174 participants

    Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03233802, the US trial registry maintained by the National Library of Medicine. NCT03233802 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.